AI Drug Discovery

This field covers the use of machine learning and other AI models to help find new drug targets, design candidate molecules, predict how those candidates may behave, and make clinical trials run more efficiently.

Every other field here depends partly on how quickly new therapeutic candidates can be found and tested. AI tools that speed target identification or trial design could compress timelines across geroscience, gene therapy, and rejuvenation research alike.

That kind of acceleration would support the broader goal of Longevity Escape Velocity: reaching a point where advances across multiple medical fields extend healthy lifespan faster than time passes.

• AI-designed candidates: Molecules designed with AI that enter preclinical or clinical testing.
• Prediction benchmarks: Published measures of prediction accuracy, such as binding affinity or toxicity.
• Trial workflows: AI tools adopted in real trial design or patient-matching.
• Independent validation: Checks of AI-generated predictions against laboratory or clinical results.

• A benchmark improvement with no laboratory or clinical follow-up.
• General AI capability announcements unrelated to longevity or drug discovery.
• Marketing claims about AI that describe no method or result.

• The lab gap: Benchmark performance often does not translate into real-world laboratory success.
• Training data: High-quality data specific to aging biology remains limited.
• Validation cost: Confirming AI predictions still requires slow, expensive laboratory and clinical work.

Fastest growth and highest current score of the eight, paired with a deliberately LOW maximum contribution. AI is an accelerator of other fields, not an independent source of healthy years: it compresses discovery while trials, biology and regulation remain rate-limiting. Assigning AI a large direct contribution is the single most common way these forecasts go wrong, and the reason optimistic timelines cluster in the 2030s.

This readiness score is a published model input, not a measurement or clinical forecast. It summarizes the field under the assumptions documented in the model and does not predict that any specific intervention will succeed. It should be treated as an evolving assessment, not a guaranteed roadmap.